Pfizer, Astellas To Launch Caduet Combination Tablets In Japan

Pfizer Japan (Pfizer) and Astellas Pharma (Astellas) to launch the combination drug of hypertension treatment and hypercholesterolemia treatment Caduet combination tablets (generic name: amlodipine besylate and atorvastatin calcium) on December 2, 2009 in Japan.

Reportedly, Caduet combination tablets is an oral combination drug of a hypertension treatment Norvasc tablets (generic name: amlodipine besylate) sold by Pfizer and a hypercholesterolemia treatment Lipitor tablets (generic name: atorvastatin calcium) co-promoted by Pfizer and Astellas.

Caduet combination tablets is a single tablet to combine the most prescribed drugs for hypertension and hypercholesterolemia to help with both treatments, and it is expected to improve medication adherence.

The drug is now approved in more than 70 countries/areas, and Pfizer has obtained approval to manufacture and market Caduet combination tablets in Japan on July 7, 2009. Moreover, Pfizer is also responsible for manufacturing and sales of Caduet combination tablets, and Pfizer and Astellas will co-promote it.

The companies said that they have established a good partnership through co-promotion of Lipitor tablets. The companies are committed to work hard to maximize the product value of Caduet combination tablets and expect to further contribute to hypertension and hypercholesterolemia treatment.